• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    METHOD FOR OBTAINING N-SUBSTITUTED 2-CYANASYRIDINES DERIVATIVES of the general formula -CN R 47 NR where RI is hydrogen or methyl R is unbranched or branched C -C ..- alkyl, allyl, 2-methylmercaptobenzyl7 3,4-dimethoxybenzyl5 4-m-allyl, 2-methylmercaptobenzyl7 3,4-dimethoxybenzyl 5 4-m -ethoxycarbonate-2-methylbenzyl, 4 hydroxybenzyl, trifluoromethylbenzyl, 2-chloro 1 enyl, 5-methyl-2-nitrobenzyl, cyclopropyl, 2-methoxyethyl, 2,2-dimethoxyethyl, phenoxyethyl, 2-hydroxyethyl, 2,2-dhloroethyl , 2-chloroethyl, cyclohex-1-ennemethyl, 2-tenyl 2-furylmethyl, 2-me. Ethylallyl ,. 1-adamantyl, phenyl, Su-C-alkoxycarbonyleth, C -Cj-alkoxycarbonylmethyl, tetrahydropyran-4-yl, 5-methoxycarbonyl-2-tenyl, 5-methoxycarbonyl-2-furfuryl, 2-butenyl, 5-methylpyrimidine-4- ylmethyl, 2-hydroxy-6-methylpyridin-3-yl-yl, methyl-1,6-dimethyl-2-oxopyridin-3-yl, methyl-2-methoxy 6-methylpyridin-3-yl, methyl-2 , 5-dimethylpyridin-4-yl, methyl 4-methyl-C thiazol-2-yl-methyl, 2-prop-ynyltetrahydrofurfuryl, L-3-methyl-mercaptopropyl, 2- j, methyl methylsulfonylethyl, zincna Sshch mil, 3 -butINIL, 2-NORBORNSH1,;:; pyrimidin-2-ylmethyl, 5-carboxy-2-tenyl or 5-carboxy-2-furfuryl, characterized in that 4. A compound of the general formula: HQh RI-CH-C-CN P1 Hall L where R, - has the indicated meanings; Hat and Halj - chlorine or bromine; L is hydrogen or, together with Hat, has a valence bond, is reacted with an amine of the general formula 1 and has the indicated meanings, and the
    公开号:SU1145927A3
    申请号:SU792791952
    申请日:1979-08-01
    公开日:1985-03-15
    发明作者:Бозиес Эльмар；Бергер Херберт；Кампе Вольфганг；Бикер Уве；Графе Альфред
    申请人:Берингер Маннхайм Гмбх (Фирма)；
    IPC主号:
    专利说明:

    the compound is isolated or directly treated.
    145927
    an H-Na1 cleavage agent such as triethylamine or triethanolamine.
    This invention relates to the preparation of new N-substituted 2-cyanazyridine derivatives, which have immuno-stimulating activity. There is a method for the irradiation of N-substituted 2-cyanaziridine by the interaction. For example, 5 253-dibromopropionitrila; benzylamine and triethylamino1-l, the purpose of the invention is to develop, on the basis of a well-known method, a method of obtaining new compounds with valuable pharmacological properties. The goal is achieved according to the method of obtaining H-substituted 1 derivatives of 2 cyanaziridines of the general formula H: where RR is hydrogen or methyl / unbranched or branched C, -C alkyl5 allyl, 2-methylmercaptobenzyl, 3 54-dimethoxybenzyl 5 4 methylbenzyl, 3-ethoxycarbonyl 2 methylbenzyl5 4hydroxybevzyl, trifluoromethylbenzi.p, 2-chlorobenzyl., 5-methyl-2-nitrobenzyl5 cyclopropyl, 2 methoxy ethyl 2; 2-dimethoxyethyl5, phenoxyethyl 2-hydroxy-ethyl, 2,2-dichloroethyl, 2-chloroethyl, cyclohexyloxy-2-hydroxy-ethyl, 2,2-dichloroethyl, 2-chloroethyl, cyclohexylethyl 2-hydroxy-ethyl, 2,2-dichloroethyl, 2-chloroethyl, cyclohexylethyl 2-hydroxy-ethyl, 2,2-dichloroethyl, 2-chloroethyl, cyclohexylethyl 2-hydroxy-ethyl, 2,2-dichloroethyl, 2-chloroethyl, cyclohexylethyl 2-hydroxy-ethyl, 2,2-dichloroethyl, 2-chloroethyl, 2-cyclohexyethyl, 2-hydroxyethyl, 2,2-dichloroethyl, 2-chloroethyl, cyclohexylethyl 1 ™ enylmethyl, 2-tenyl5 2 - furi methyl, 2-methylallyl, mantil, phenyl, C-C -alk ok sicarbonylethyl, ,, alkoxycarbonylmethyl; tetrahydropyran-4-yl, 5-methoxy carbonyl-2-vinyl, 5-methoxy carbonyl-2-furfuryl 5 2-butene; 5 methylpyrimidine 4-methyl-2, 2-hrschrrksi-6-me. Tylgarpapin-3-yl, methyl-1,6-dimethyl-2-oxo-pyridin-3-ylg methyl-2-methoxy 6-methylpyridin-3-yl, methyl-2,5-dimethylpyridin-4-yl, methyl . -4-methylthiazol-2-yl-metsh1, 2-propynyltetrahydrofurfurylLg 3-methyl-mercaptopropyl, 2-methylmethylsulfonyl, cinnamyl, 3-butynyl, 2-norbornyl, pyrimidine-2-yl-methyl, 5-carboxy-2-tenyl and 5-carboxy-2-furfuryl, comprising the fact that a compound of the general formula BH-CH-C-CN I Hall L where K. is the indicated values; ttat and Hatj - chlorine or I. - hydrogen or, together with Hat, means a valence bond, is reacted with an amine of the general formula K-Shg, where R - has the indicated values, and the compound thus formed gives Or directly. is treated with a cleavage H-NaC agent, such as triethylamine or triethanolamine. Example 1. 1-Allyl-2-cyanaziridine, To 2-bromoacrylnitrile in 250 ml of toluene is added dropwise with stirring, a solution of 28.5 g of allylamine and 51 g of triyeamine in 250 ml of toluene. Then, for 3 days at room temperature, stirring, filtration, evaporation of the filtrate, transfer of the residue, to ether, extraction in ice-cold dilute hydrochloric acid, washing in ice-water to neutral reaction and passing the resulting solution through 400 g of deactivated alumina . After evaporation, double distillation is carried out. Output 28.6, t / kip. and ZZ-ZZ C. Similarly, by treating with 2-bromoacrylonitrile with appropriate amines and subsequent purification over silica gel and / or through a column with deactivated alumina, the following compounds are obtained: (h) 2-1 wed-1- (2-hydroxyethyl) -aziridine , oily product, yield 31, and) 3- (2-cyanaziridin) -1-yl-ethyl ester of propionic acid, m.p. 0,, yield 33% (solvent dioxane); l) 2-cyan-1- (4-hydroxybenzyl) -aziridium, t. tech. il2-114C, yield 37% (solvent - ethanol); m) S-2- (+) - 2-cyano-1-aziridine 3-methyl propionate, t. 88-91 with from diisopropyl ether, rotj + 99.4 with 1 (methanol) i; n) 2-cyano-1- (cyclohex-1-enylmetesh1) -azyridine t. SW-SW C, yield 42.9%, o) 2-cyan-1- (2-tenyl) -aziridine 5 t. Bales. , 90-92 C, yield 20% (reaction time 10 days) j p) 2-cyano-1- (2-furylmethyl) -aziridine so bp. . 0 100-101С, yield 8.1% (reaction time 10 days) p) 2-cyan-1- (2-methylallyl) -aziridine t. Bale. 9 36-38 0, yield 16.4%, c) 1- (1-adamantyl) -2-cyanaziridine t. Tech. 62-64 C. yield 31.8% (solvent is dioxane). Example 2. 1-tert-Butyl-2-cyanairidine. 6.0 g of 2-bromo-3-tert-butylaminopropionitrile-hydrobromide (obtained by treating 2,3-dibromopropionitrile with tert-butylamine, etc., 188-190s) is dissolved in 30 methanol and heated with 23 g of triethyolamine for 4 h with reverse ottokon. Then the resulting solution is evaporated, neutralized 2 n. with sulfuric acid, extracted with ether. The obtained ether fraction is dried and extruded. It is then distilled. Output 1, 3%, t. Kip. D2 32-34 ° C. Tech. 33-54 C In a similar way, it is obtained by treating: a) 2-bromo-3-p-pentylamino-propionitrile-hydrochloride (obtained by treating 2,3-dibromopropionitrile-p-pentyl-amine, t.the 133-133C) with triethanolamine 2 -cyan-t-p-pentilaziridin, t. Kip. (, 43% yield., b) 2-bromo-3- (carboxymethylamino) propionitrile hydrochloride (prepared by treating 2,3-dibromopropionitrile glycinethylether t. tech. 70-75 ° C) with triethanolamine 2-cyano-1-aziridine- ethyl acetate t, kip. about 88-90 ° C, vkod 34%; c) 2-bromo-3- (1-carbomethoxymethyl) amino 3-propionitrile (obtained by treating. 2, 3-dibromopropionitrile with 1-alanine methyl ester, oily substance) with triethylamine S-2-C (+) -2-cyano-1 -aziridium-methyl propionate, t. tech. 88-91 ° C, from diisopropyl ether, + 99.4 ° C, with 1 (methanol), Example 3. 1-Allyl-2-cyano-3-methylaziridine. 13.4 g of crotonitrile are treated at room temperature for 2 hours with 32 g of bromine, then the solution is heated to decolorization, dissolved in 100 ml of ether, cooled, then added dropwise 20.2 g of triethylamine in 30 ml of ether and cooled in for an hour ppi with constant stirring. A mixture of 20.2-triethylamine and 11.4 g of allylamine in 100 ml of ether is added to the suspension and left to stand for 4 days with stirring. The precipitate is filtered off with suction, washed with ether, and the dried ether solution is passed through 230 g of deactivated aluminum oxide. Then evaporation and fractionation are carried out. The code 10.3.d. 42.2%. T. Kip. o, i55-37 C. Example 4. 1-Benzylaziridin-2-ethyl carboxylic ester. To 52 g of 2,3-dibromopropionic acid ETHENNA in 230 ml of toluene with stirring, add 33.3 ml of triethylamine and after 2 hours a solution of 21.4 benzylamine in 230 ml of toluene, then stir for 3 days at room temperature. Repeatedly extracting the suspension with water, drying the organic phase, subjecting it to evaporation, dissolving the residue in ether and passing the solution through 400 g of deactivated alumina. Then, it is recharged and fractionated. Yield 30.7% 75% T. flow 98-101 ° C. In a similar manner, 2,3-di-bromopropionic acid ethyl ester is obtained by treatment; a) with methylamine 1-methylaziridine -2-ethyl ester of carboxylic acid, t. CAT, 70-72 ° C, yield 40%, b) with allylamine 1-allylaziridine -2-ethyl ester of carboxylic acid. m.p. 9 -E2c, 24% yield, Example 5, Analogously to Example 1, by treatment with 2-bromoacrylonitrile, you get: a) with 2 methyl mercaptobenzylamine 2-cyano-1- (2-methyl mercaptobenzyl) -aziridine, oily product, 54% yield ; b) with 354-dimethoxybenzylamine 2-cyano-1 (354-dimethoxybenzyl) -aziridine, oily product, yield. c) with 4-methylbenzylamine 2-cyan -1- (4-methylbenzyl) -aziridine, t, kip. (, pg1 13-115 ° С, yield 23%. g) with cyclopropylamine 2-cyan-1-cyclopropyl-aziridine t. bale. yield 22%, d) with 2-methyl-3-carbethoxy-benzine amine 2-cyan 1- (2-methyl-3-carbetho C-benzyl) -aziridine 5 t. bale. 0.01, t. Tech. 40-43 ° C, yield 20% of theoretical. c) with 1- (2-chloroethyl) -2-cyanaziridine 2-chloroethylaminohydrochloride (solvent - dioxane), bp, 74 ° C, yield 5.1%. g) with 4-aminotetrahydropyran 1- (4-tetrahydropyranyl) 2-cyanazyridine) (solvent is dioxane), so on. 74-76 ° C, yield 13.2%, h) with 2-methoxyethylamine 2-cyan -1- (2-methoxy-ethyl) -aziridine, t. Bale. g., yield 17.5%. i) with 2-phenoxyethylamine 2-cyan -1- (2-phenoxy-ethyl) -aziridine, t. Kip. 005, yield 38.8%. Example 6. In analogy to example 1, it is obtained by treating 2-br (.) M-lcrylonitrile. } with 3-methoxycarbonyl-2-tenyl tii Ui, 4. 11.11.: N-1- (S-methoxy-carbo76 nyl-2-tenyl) -aziridine, t, tech. 51 54 C, yield 49%, b) with 5-methoxycarbonyl-2-furfurylamine 2-cyano-1- (5-methoxycarbonyl-2-furfuryl) -aziridine, m. Tech. 8689 C, yield 46%, c) with 2,2-dichloroethylamine-2-cyan-1- (2, 2-dich: laurethyl) -a ziridine, t. Bale. 0.1 94-95 ° C, yield 16%, g) with but-2-enylamine 1- (but-2-enyl) -2-cyanaziridine, t „bale. , yield 70%, d) 2-cyan-1- (5-methylpyrimidin-4-yl-methyl) -aziridine, 5-methylpyrimidin-4-yl-methylamine, t, tech. 8892 ° С (from isopropanol), yield 56%. g) with 2-hydroxy-6-methylpyrimidin-3-yl-methylamine-2-11. Ian-1- | (2-hydroxy-6-methylpyrimidine-3-sh1) -methyl 3-aziridine, t. tech. 187-190С (from water), yield 47%, g) with aminoacetaldehyde dimethyl acetal 2-cyano-1- (2,2-dimethoxy-1-ethyl) -aziridine, t. Bale. (9092 C, yield 70% -, g) with 1,6-dimethyl-2-oco-pyridin-3-yl-methamine-2-ian-1-L (I 6-dimethyl-2-oco-pyridine- 3-yl) -methyl-3-azipidine 5 That tech. 82-84 ° C, yield 78%. i) with 2-methoxy-6-methylpyridin-3-yl-methylamine-2-cyan-1- (2-methoxy-6-methylpyridin-3-yl) methyl-aziridine, m. tech. 70-73 0 (from isopropanol), 69% yield, c) from 2,5-dimethyl-pyrimidin-4-ylmethylamine-2-cyano-1-C2,5-dimethyl-pyrimidine-4-id) methyl-aziridine , t.tek. 88-92 C (from isopropyl), yield 82%; l) h 4-methylthiazol-2-yl-methylamine-2-cyan-1- (4-methylthiazol-2-yl-methyl) -aziridine, T. tech. JS-TS C, yield 21%; m) - with prop-2-yl-amine-2-cyan-1- (prop-2-icyl) -aziridine, t. Kip. о.,, yield 28%, n) with tetrahydrofurfurilamine 2-cyan-1-tetrahydrate, rofurfuryl-aziridine, t. kip,, yield 20%, o) with 3-trifluoromethylbenzylamine 2-cyan-1- (3-trifluoromethyl) -aziridine, t. Kip. , yield 31%. p) with 3-methylmercaptopropylamine 2-cyan-1- (3-methylmercaptopropyl) -aziridine, t. bale. d 110C, yield 18%; p) with 2-methylsulfonyl ethyl 2-cyano-1- (2-methylsulfonyl ethyl) -aziridine, oily substance, yield 47%, c) with phenethylamine 2-cyano-1-phenyl-aziridine, m.p. “122-124 С, yield 18%, t) with 1-cinnamyl-2-cyanaziridine cinnammine, t. Bale. 138-14 ° C, yield 13%; s) with but-3-ynilamine-1- (but-3-ynyl) -2-cyanaziridine, b.p. , yield 68%, f) with 2-norbonylamine 2-cyano-1 (2-norbonyl) aziridine, t. bale 84, yield 20%, x) with chlorobenzylamine 1- (2-chlorobenzyl) -2-cyanaziridine, t. tech. 5557 C (from isopropanol), yield 36%; h) with pyrimidine-1-2-ylmethylamine 2-cyano-1- (pyrimidine-2-yl-methyl) -aziridine, t. tech. 72-76 ° C (from isopropanol), yield 33%, w) with 5-methyl-2-nitrobenzylamine -2-cyano-1- (5-methyl-2-nitrobenzene1) -aziridine, m. Tech. 95-96 ° C (from isopropanol), yield 41%, y) with K - (-) - alanine methyl ester K - (-) - 2- (L -) - 2-cyano-1-aziridine-methyl ester of propionic acid, t. tech. -9p-91C (from diisopropyl ether), yield 12% - - 99.1 (s 1; in methanol). Example 7. L - (-) - i- (L) - (- Phenylethyl) -aziridine-2-ethyl ester of carboxylic acid and D - (+) - 1, - (L -) - (- Phenylethyl) -aziridine- 2-ethyl ester of carboxylic acid. To 26 g of 2,3 dibromopropionic acid ethyl ester in 60 ml of ethanol, 15 g of triethanolamine in 20 ml of ethanol are added with stirring and, after 1 h, a solution of 12.1 g of b - (-) - phennylethylamine in 20 ml of ethanol and solution 15 g of triethanolamine in 20 ml of ethanol. The suspension is stirred for 12 hours at room temperature, sucked off, the filtrate is subjected to evaporation, and the residue is passed through a column of silica gel and divided into diastereomers (aluant is a mixture of ether and ligroid - 2: 1). The yield of the b, b-isomer is 39%, an oily substance, jjj -90 °, (with “IB ethanol). Yield D, D-H30MepoB - 47%, oily substance - 53.2 ° (with 1 in ethanol). In a similar way, by treating with ethyl 2,3-; ibromopropionic acid P - (+) - phenylethyl-amine, the following is obtained: a) b - (-) - 1- (P -) + (- phenylethyl) -aziridine-ethyl ester 2- carboxylic acid, oily substance, yield 39%, roiJi, 57.9 (with 1 in ethanol); b) B - (+) - 1- (B -) + (- phenylethyl) -aziridine-ethyl ester of 2-carboxylic acid, oily lower substance, yield 39%, 0 + 89.7 (with 1 in ethanol) . Intravenous administration of f-carbamoyl-2-cyanosyridine in rats causes a strong increase in leukocytes and lymphocytes, while the number of erythrocytes remains almost unchanged 2, a significant increase in liver cells producing antibodies is observed; For this reason, this product is used as an immunostimulating therapeutic agent for bacterial and viral infections. The insignificant stability of this substance in solutions and the incomplete efficacy in oral administration are disadvantages of this preparation.a. For this reason, the task was to select or develop such an immunostimulating therapeutic agent, which, with equal or greater efficacy and low toxicity, would not have side effects, would have been more stable and easier with oral administration. The compounds obtained by this method have an immunostimulating action. For evidence of an immunostimulatory effect (the effect of acute infection with Escherichia coli (108) in mice was investigated using an immunostimulant from compounds of the general formula (1) (for example, 1-allyl-2-cyanaziridine (B)), while giving out subtherapeutic doses of choramphenicol (A) Experimental conditions: in each case, 20 female MMRI mice (25-30 g) were infected intrapine for a day .. 9-1
    ritonally IjOxio with embryos of Escherichia coli per animal Treatment was carried out as follows.
    Group 1 - orally 40 mg / kg A, diluted in 0.5% tylosis.
    Group 2 - orally 13.4 mg / kg B dissolved in 055% tylosis.
    The percentage of surviving animals after infection
    70 o
    13.4 - (- 13.4
    100
    15
    3.3
    ten,
    65 -3.3
    ABOUT
    Troll O
    In addition, when checking leukocytosis, an increase in the number of leukocytes after oral administration of compounds of the general formula (.1)) was found.
    In each case, 10 females of adult Spague-Dawby rats of the empty stomach collected blood from the retroorbital vein plexus, and the number of leukocytes was counted using a Coulter Counters counter. Then investigated
    14592710
    Group 3 - oral 40 mg / kg A + f 13.4 mg / kg B dissolved in O, 5th tylose.
    Group 4 - orally 10 mg / kg, dissolved in 0.5% tylosis.
    Group 5, oral 3.3 mg / kg B, dissolved B 0.5% tylosis.
    Group 6 - orally 10 mg / kg A, dissolved in 0.5% tylosis.
    Group 7 (control) - tylosis.
    Results;
    65 o
    65 o
    65 o
    70 o
    100
    100
    100
    0
    15
    15
    15
    15
    ten
    ten
    ten
    ten
    50
    50
    50
    50
    ABOUT
    ABOUT
    ABOUT
    ABOUT

    Compounds in doses of 200 mg / kg were administered orally, dissolved in 0.5% tylosis or as a suspension. After 4 days on an empty stomach again in the morning
    blood was taken from the retroorbital vein plexus, the number of leukocytes was counted on a Coulter Counters counter, and then the average values were calculated with standard g
     reject my.
    chlorine 1phenicol5
    1-allyl-2-cyanaziridine,
    2-cy9H-1-methylazirndin |
    2-cyai-1-y-propyl eiridine
    1-benzyl-2-cyanaziridine,
    3- (27 Cyanaziridin-1-yl) -acrolein-,
    Table continuation
    1311459271
    G is 3- (2--1 dianaziridin-1-yl) ethyl ester of acrylic acid;
    H -1-phenyl-1- (2-carbamo-1-cyridine-1-yl) 2-cyanoethylene
    1 - 2-cyan 1 isopropylaziridine
    1 2-Cyam-1 (2 tenyl) aziridine,
    K - 2 1shchan-1- (2 methylallyl) - aziridine5
    L 1- (2-chloroethyl) -2-cyanaziridine $
    M - 2-cyan - 1- (3-Trifluoromethylbenzyl) aziridine5
    N - 2 cyan-1- (5-carboxy) -2-furfuryl) aziridine
    O 2- -cyan 1- (5-methoxycarbonyl-2-tenyl) -aziridine;
    P 2-cyan 1 (252 dichloroethane 1) aziridine;
    Q (but 2 - enyl) 2-sch1anaziridin5
    R (5-methyl-2 nitrobenzyl) is aziridine;
    S 1- (2 Chlorobenzyl) -2-1 Dianazyridic;
    T 2 cyan-1 - (5 - methylpyrimidine - 4-ylnetil) -aziridine5
    U-I, (-) (b) (phenylethyl) -aziridine;
    V-D (+) - 2 cyano-t- (L -) - (phenylethyl) -aziridine;
    W-L- (-) 2-cyan - 1 - (D-) + (-phenylethyl) -azyridine.
    X - 2-cyan-1- (pyrimidin-1-ylmeti, p) aziridine5
    Z - - L (2 methoxy-6-ketylpyri: 4idin-3-yl) methyl} -aziridine.
    2-11 anaziridine, substituted manual, in contrast to the known
     nitrogen alkyl groups possess an aziridine derivative in Ames-mecme
    weak in action. Compounds are extremely weak or nearly
    The results obtained by the proposed CRG show no mutagenic properties.
    权利要求:
    Claims (3)
    [1]
    METHOD FOR PRODUCING N-SUBSTITUTED 2-CYANAZYRIDINE DERIVATIVES OF THE GENERAL FORMULA
    R L where R * is hydrogen or methyl;
    R - unbranched or branched C ^ -C -alkyl, allyl,
    [2]
    2-methylmercaptobenzyl, 3,4-dimethoxybenzyl, 4-methylbenzyl, 3-ethoxycarbonyl-2-methylbenzyl, 4-hydroxybenzyl, trifluoromethylbenzyl, 2-chloroglyzyl, 5-methyl ~ 2-nitrobenzyl, cyclopropyl, 2-methoxyethyl, 2,2-dimethoxyethyl, phenoxyethyl, 2-g'hydroxyethyl, 2,2-dichloroethyl, 2-chloroethyl, cyclohex-1-enylmethyl, 2
    -tenil, 2-furylmethyl, 2-methylallyl, 1-adamantyl, phenyl, Cy-C 2 -alkoksikarboniletil, Cy-C 2 -alkoksikarbonnlmetil, tetrahydropyran-4-yl, 5-methoxycarbonyl-2-thenyl, 5-methoxycarbonyl-2 furfuryl, 2-butenyl, 5-methylpyrimidin-4-yl-methyl (
    2-hydroxy-6-methylpyridin-3-yl, methyl-1,6-dimethyl-2-oxopyridin-3-yl, methyl-2-methoxy 6-methylpyridin-3-yl, methyl-2,5-dimethylpyridin-4 -yl, methyl-4-methylthiazol-2-yl-methyl, 2-prop-ynyltetrahydrofurfuryl,
    [3]
    3- methyl mercaptopropyl, 2-. -methylsulfonylethyl, zinc; mil, 3-butynyl, 2-norbornyl, pyrimidin-2-yl-methyl, 5-carboxy-2-tenyl or 5-carboxy-2-furfuryl, characterized in that the compound of the general formula
    Hqh
    Ki ~ CH-C-CN! I NOSCH L 'where R, - has the indicated meanings;
    At £ 1 and Hat 2 - chlorine or bromine;
    L - hydrogen or together with Hat 3 have a valence bond
    SU „, 1145927 is reacted with an amine of the general formula I-DN 2 , where R - has the indicated meanings, and the resulting 1145927 compound is isolated with an H-Na1-cleaving agent, or is treated directly with triethylamine or triethanolamine.
    t
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0527736B1|1997-04-16|Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
    DE2655500C2|1988-12-22|
    DE3814549A1|1989-05-18|N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN AND 1-DESOXYMANNONOJIRIMYCIN, METHOD FOR THE PRODUCTION AND USE THEREOF IN MEDICINAL PRODUCTS
    SU1145927A3|1985-03-15|Method of obtaining n-substituted derivatives of 2-cyanethyleneimine
    DE2527065A1|1976-01-08|5-PROPYLTHIO-2-BENZIMIDAZOLE CARBAMIC ACID METHYLESTER
    EP0014976B1|1982-04-07|N-substituted 2-cyanaziridines, methods for their preparation and medicaments containing them, correspondingly substituted aziridine-2-carbonamides and their preparation
    DE1795711B2|1978-09-21|Substituted benzimidazoles, processes for their preparation and anthelmintic compositions containing them
    DE3509618A1|1986-09-18|SS LACTAM ANTIBIOTICS, METHOD FOR THE PRODUCTION AND THEIR USE AS A MEDICINAL PRODUCT
    EP0338308A2|1989-10-25|Substituted N-glycosylamides, process for their preparation and their use as medicaments
    DE1250828B|1967-09-28|Process for the preparation of the spasmolytically active 6,7,3 ', 4' - tetraethoxy-1-benzylidene-1,2,3,4 tetrahydroisoquinoline and its salts
    EP0433928B1|1995-03-15|2-Formylbenzylphosphonic acid derivatives, their preparation and their use for treatment of diseases caused by viruses
    DE4003054A1|1991-08-08|USE OF BENZYLPHOSPHONIC ACID DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY VIRUSES
    RU2102390C1|1998-01-20|N-|pyrazine- -2-carboxamide possessing anti leprotic and antituberculosis and immunotropic activity, method for their production
    DE2147103C3|1975-07-17|Imidazo square bracket to 4.5-square bracket to pyridine
    DE4021006A1|1992-01-09|PYRIMIDINE DERIVATIVES, THEIR PRODUCTION AND USE AND THE MEDICINAL PRODUCTS CONTAINING THEM
    DE2624856A1|1977-12-22|Anthelmintic thio-barbituric acid derivs. - have |-benzyl-thiocarbamoyl substit. and are esp. useful for control of liver flukes
    DE2147852A1|1972-03-30|New penicillins and processes for their production
    DE2839224C2|1990-10-25|
    RU2039045C1|1995-07-09|2,4-dichloro-5-nitrobenzoate-2-pyridyl ammodium having analgetic activity
    DE2065047C|1973-03-15|3- | -3H-1,2,3-triazinon- |. Eliminated from: 2012094
    EP0233206B1|1990-03-21|Sugar-containing dipeptides and their pharmaceutical use
    DE2808153A1|1979-09-06|6-Pyrimidyl:ureido:acetamido-penicillin derivs. - used as antibacterials, feedstuff additives and preservatives
    CH578553A5|1976-08-13|Nitroquinazolinone antivirals, anti-inflammatories and - analgesics - prepd by direct nitration
    DE1271118B|1968-06-27|3- | -3H-benzo-1, 2, 3-triazinon- |
    DE1275537B|1968-08-22|Process for the preparation of N- | -heterocycles
    同族专利:
    公开号 | 公开日
    IE48462B1|1985-01-23|
    MY8600045A|1986-12-31|
    CA1142530A|1983-03-08|
    FR2432317A1|1980-02-29|
    NO152413C|1985-09-25|
    IT1123503B|1986-04-30|
    DK156431B|1989-08-21|
    BE878020A|1980-02-01|
    DE2833986A1|1980-02-21|
    JPS6243991B2|1987-09-17|
    JPH0257523B2|1990-12-05|
    NL7905855A|1980-02-05|
    CS227301B2|1984-04-16|
    ATA531479A|1985-05-15|
    NZ191169A|1981-01-23|
    FR2432317B1|1983-03-18|
    FR2445316B1|1983-07-29|
    NL187239C|1991-07-16|
    AU524572B2|1982-09-23|
    ZA793966B|1980-08-27|
    US4409236A|1983-10-11|
    US4321194A|1982-03-23|
    GB2026863B|1983-03-30|
    IT7924769D0|1979-07-30|
    DD145267A5|1980-12-03|
    EG14369A|1983-12-31|
    PT70009A|1979-08-01|
    SE445552B|1986-06-30|
    FR2445316A1|1980-07-25|
    ES483116A1|1980-04-16|
    JPS63258415A|1988-10-25|
    HU184610B|1984-09-28|
    FI792393A|1980-02-04|
    AR228945A1|1983-05-13|
    NO792545L|1980-02-05|
    AU4930879A|1980-02-07|
    NO152413B|1985-06-17|
    JPS5522694A|1980-02-18|
    IL57939D0|1979-11-30|
    GB2106896A|1983-04-20|
    DK320379A|1980-02-04|
    IE791478L|1980-02-03|
    IL57939A|1985-02-28|
    DK156431C|1990-01-22|
    FI70570B|1986-06-06|
    DE2833986C2|1988-04-07|
    LU81563A1|1980-08-08|
    OA06310A|1981-06-30|
    GR74424B|1984-06-28|
    YU188179A|1983-06-30|
    GB2026863A|1980-02-13|
    US4410532A|1983-10-18|
    KR830000902A|1983-04-28|
    HK13285A|1985-03-01|
    PL217527A1|1980-07-01|
    KE3493A|1985-02-01|
    KR860000320B1|1986-04-09|
    PL126531B1|1983-08-31|
    YU41169B|1986-12-31|
    AT379382B|1985-12-27|
    SG85784G|1985-06-07|
    SE7906461L|1980-02-04|
    CH645540A5|1984-10-15|
    FI70570C|1986-09-24|
    GB2106896B|1983-08-17|
    PH19007A|1985-12-03|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE1470223A1|1962-09-05|1969-12-04|Siegfried Ag|Process for the preparation of new nitrogen-containing heterocycles|
    DE2528460A1|1975-06-26|1977-01-13|Boehringer Mannheim Gmbh|1-Carbamoyl 2-cyano aziridine as immunostimulant - for therapy of bacterial and viral infections|
    DE2530960A1|1975-07-11|1977-01-27|Huels Chemische Werke Ag|N-substd. aziridinyl oxazolines - useful e.g. as corrosion inhibitor, antistatics and intermediates for pharmaceuticals or polyethylene imines|
    DE2538672A1|1975-08-30|1977-03-10|Boehringer Mannheim Gmbh|Carcinostatic or immunostimulant medicaments - contg. propionic acid deriv. precursors of -carboxy-isoserine|
    CA1092606A|1976-10-05|1980-12-30|Herbert Berger|1--2-cyano-aziridines and the preparation thereof|
    GB1550065A|1976-10-29|1979-08-08|Inst Organicheskogo Sinteza Ak|Pharmaceutical composition processing antitumour activity|
    DE2656240C2|1976-12-11|1983-11-03|Boehringer Mannheim Gmbh, 6800 Mannheim|New aziridine derivatives, processes for their preparation and pharmaceutical agents|
    AR218645A1|1976-12-11|1980-06-30|Boehringer Mannheim Gmbh|PROCEDURE FOR PREPARING ESTER DERIVATIVES FROM 1-AZIRIDINE-CARBOXYL ACID|DE3446713A1|1984-12-21|1986-06-26|Boehringer Mannheim Gmbh, 6800 Mannheim|N-SUBSTITUTED AZIRIDINE-2-CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE SUBSTANCES|
    JPS6287512A|1985-10-11|1987-04-22|Boehringer Mannheim Gmbh|Selective immunosuppressive|
    US4925835A|1986-05-01|1990-05-15|Sloan-Kettering Institute For Cancer Research|Aziridinyl putrescine containing compositions and their uses in treating prostate cancer|
    KR19980083844A|1997-05-19|1998-12-05|이웅열|New aziridine derivatives and preparation method thereof|
    FR2776292B1|1998-03-20|2004-09-10|Oncopharm|CEPHALOTAXANES SUPPORTING THE SIDE CHAIN AND THEIR SYNTHESIS PROCESS|
    KR20010000195A|2000-08-10|2001-01-05|하현준|Process for preparing - and -aziridine-2-carboxylates, and - and -2-hydroxymethylaziridines|
    US20030129222A1|2000-11-21|2003-07-10|Gabriel Lopez-Berestein|Liposomal imexon|
    CA2431947A1|2000-11-21|2002-05-30|Gabriel Lopez-Berestein|Composition comprising an imexon or derivatives thereof and lipids|
    US6982263B2|2001-06-08|2006-01-03|Boehringer Ingelheim Pharmaceuticals, Inc.|Nitriles useful as reversible inhibitors of cysteine proteases|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE2833986A|DE2833986C2|1978-08-03|1978-08-03|
    [返回顶部]